i nearly lost my daughter to menb - trumenba · what is menb? meningitis b (also known as menb) is...

Not an actual MenB survivor. For illustrative purposes only.

For more information, visit TRUMENBA.com

INDICATION• Trumenba is a vaccine indicated for individuals 10 through 25 years of age

for active immunization to prevent invasive disease caused by Neisseria meningitidis group B

• The effectiveness of the two-dose schedule of Trumenba against diverse N meningitidis group B strains has not been confirmed

SELECTED SAFETY INFORMATION• Trumenba should not be given to anyone with a history of a severe allergic

reaction after a previous dose of Trumenba

• Some individuals with weakened immune systems may have a reduced immune response

Please see full Important Safety Information on page 5, and click here for full Prescribing Information.

I nearly lost my daughter to MenB

Help protect your teen against meningococcal group B disease (MenB) by vaccinating with TRUMENBA1

https://www.trumenba.com/

http://labeling.pfizer.com/ShowLabeling.aspx?id=1796

What is MenB?Meningitis B (also known as MenB) is an uncommon but potentially deadly bacterial infection that attacks the linings of the brain and spinal

cord, called the meninges, and can also cause an infection of the blood.2-4

The incidence of MenB in adolescents and young adults peaks at age 19.5

Even if your teen previously received a vaccine for meningococcal

disease (MCV4 vaccine), a separate vaccine is required to help protect

against MenB.6

— MCV4 protects against 4 common forms: A, C, W, and Y, but

does not protect against MenB, which represents approximately

60% of all meningococcal disease cases among adolescents

and young adults in the US6,7

MenB can spread through typical sharing behaviors3,8

Close-quartered living

Kissing Sharing utensils





2

For survivors, MenB can lead to permanent disabilities9,10

Brain damage Scarring Hearing lossLimb loss

Early symptoms can seem like the flu, but MenB can lead to death within 24 hours2,4

• On average, 2 in 10 survivors may be affected by long-term or

permanent disabilities9,10

• On average, 1 in 10 adolescents and young adults who develop MenB

will die from it11

SELECTED SAFETY INFORMATION• Persons with certain complement deficiencies and persons receiving

treatments such as Soliris® (eculizumab), are at increased risk for invasive disease caused by N meningitidis group B even with receipt of vaccination with Trumenba

• As with any vaccine, vaccination with Trumenba may not protect all vaccine recipients against N meningitidis group B infections



What is TRUMENBA?TRUMENBA can help protect your teen against MenB when they

need it most.5,12

— 16 to 18 years is the age recommended by the Centers for

Disease Control and Prevention (CDC) for MenB vaccination6

Only TRUMENBA was studied at the same time in patients who also

received other common adolescent vaccines, like a meningitis vaccine

(MCV4), an HPV vaccine (HPV4) or tetanus, diphtheria, pertussis

vaccine (Tdap).1,6

TRUMENBA safety • TRUMENBA was approved by the FDA in 201413

• The safety data demonstrated that TRUMENBA was generally

well tolerated1

• The most commonly reported side effects were pain at injection site,

fatigue, headache, and muscle pain1


Vaccinate with TRUMENBA to help protect your teen against MenB




4

IMPORTANT SAFETY INFORMATION• Trumenba should not be given to anyone with a history of a severe allergic

reaction after a previous dose of Trumenba

• Some individuals with weakened immune systems may have a reduced immune response

• Persons with certain complement deficiencies and persons receiving treatments such as Soliris® (eculizumab), are at increased risk for invasive disease caused by N meningitidis group B even with receipt of vaccination with Trumenba

• As with any vaccine, vaccination with Trumenba may not protect all vaccine recipients against N meningitidis group B infections

• Fainting can occur in association with administration of injectable vaccines, including Trumenba

• The most common adverse reactions in adolescents and young adults were pain at injection site, fatigue, headache, and muscle pain. Nausea was reported in adolescents in early phase studies

• Data are not available on the safety and effectiveness of using Trumenba and other meningococcal group B vaccines interchangeably to complete the vaccination series

• Tell your health care provider if you are pregnant, or plan to become pregnant

• Ask your health care provider about the risks and benefits of Trumenba. Only a health care provider can decide if Trumenba is right for you or your child



at day 1

at day 1 6 months after dose 1

1-2 months after dose 1 6 months after dose 1

TRUMENBA2 TRUMENBA3

ACIP=Advisory Committee on Immunization Practices.

What to expect with TRUMENBATRUMENBA follows a 2- or 3-dose schedule1

• Discuss with your teen’s health care provider or pharmacist which

schedule is appropriate for your teen

• ACIP recommends 2 doses for healthy adolescents and young adults12

• ACIP recommends 3 doses for persons who are at high risk of

meningococcal disease or in a MenB outbreak situation12

Visit FindTRUMENBA.com to find the doctors’ offices, convenient care clinics, and pharmacies that offer TRUMENBA in your ZIP code

2-dose schedule for healthy teens





6

A complete dose series of TRUMENBA may help protect your teen against MenB

SELECTED SAFETY INFORMATION• Fainting can occur in association with administration of injectable vaccines,

including Trumenba

• The most common adverse reactions in adolescents and young adults were pain at injection site, fatigue, headache, and muscle pain. Nausea was reported in adolescents in early phase studies

• Text and email reminders are also available in Spanish

• Sign up to receive email reminders at RememberTRUMENBA.com

For a 2-dose series

Text “TRUMENBA2”For a 3-dose series

Text “TRUMENBA3”

Enroll in REMEMBER TRUMENBA• To receive text reminders, use your mobile device to text the appropriate

dose series code below to 37500


http://remembertrumenba.com

TRUMENBA helps protect your teen from MenB• Even if your teen previously received a vaccine for meningococcal disease

(such as the MCV4 vaccine), they are not protected against MenB6

• 16 to 18 years is the age recommended by the CDC for MenB vaccination6

• TRUMENBA follows a 2- or 3-dose schedule, completed in 6 months1

• Sign up for REMEMBER TRUMENBA for dose reminders to help ensure your

teen completes the vaccine series

Talk to a health care provider or pharmacist about vaccinating your teen with TRUMENBA

PP-TRU-USA-2058-02 © 2018 Pfizer Inc. All rights reserved. September 2018

Please see full Important Safety Information on page 5, and click here for full Prescribing Information.You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit www.vaers.hhs.gov or call 1-800-822-7967.Call 1-844-TRUMENBA (878-6362), 9 am to 7 pm ET, Monday through Friday, for more information.

References: 1. TRUMENBA [package insert]. Philadelphia, PA: Pfizer Inc; 2018. 2. Thompson MJ, Ninis N, Perera R, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367(9508):397-403. 3. Soeters HM, McNamara LA, Whaley M, et al. Serogroup B meningococcal disease outbreak and carriage evaluation at a college–Rhode Island, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(22):606-607. 4. Centers for Disease Control and Prevention. Meningococcal disease. Centers for Disease Control and Prevention website. http://www.cdc.gov/meningococcal/index.html. Updated April 9, 2018. Accessed August 1, 2018. 5. National Foundation for Infectious Diseases. Addressing the challenges of serogroup B meningococcal disease outbreaks on campuses: a report by the National Foundation for Infectious Diseases. http://www.nfid.org/meningococcal-b. Published May 2014. Accessed August 1, 2018. 6. MacNeil JR, Rubin L, Folaranmi T, et al. Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(41):1171-1176. 7. Centers for Disease Control and Prevention. Enhanced Meningococcal Disease Surveillance Report, 2016. https://www.cdc.gov/meningococcal/downloads/NCIRD-EMS-Report.pdf. Updated September 2017. Accessed August 1, 2018. 8. Tully J, Viner RM, Coen PG, et al. Risk and protective factors for meningococcal disease in adolescents: matched cohort study. BMJ. 2006;332(7539):445-450. 9. Bettinger JA, Scheifele DW, Le Saux N, et al. The disease burden of invasive meningococcal serogroup B disease in Canada. Pediatr Infect Dis J. 2013;32(1):e20-e25. 10. Borg J, Christie D, Coen PG, et al. Outcomes of meningococcal disease in adolescence: prospective, matched-cohort study. Pediatrics. 2009;123(3):e502-e509. 11. Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis. 2010;50(2):184-191. 12. Patton ME, Stephens D, Moore K, et al. Updated recommendations for use of MenB-FHbp serogroup B meningococcal vaccine—Advisory Committee on Immunization Practices, 2016. MMWR Morb Mortal Wkly Rep. 2017;66(19): 509-513. 13. Folaranmi T, Rubin L, Martin SW, et al. Use of serogroup B meningococcal vaccines in persons aged ≥10 years at increased risk for serogroup B meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(22):608-612.




SELECTED SAFETY INFORMATION• Tell your health care provider if you are pregnant, or plan to become pregnant

• Ask your health care provider about the risks and benefits of Trumenba. Only a health care provider can decide if Trumenba is right for you or your child


i nearly lost my daughter to menb - trumenba · what is menb? meningitis b (also known as menb) is...

Documents